Highlights for the quarter include:
- The Company completed the first stage of its Phase I study, the prescheduled SAD (single ascending dose) stage, on ATB-346.
- The Company began the second stage of its Phase I study, the prescheduled MAD (multiple ascending dose), and expects the study to be completed in January 2015 with the results released soon thereafter.
- The Company began trading in the United States on the OTCQX exchange under the ticker symbol “ATBPF”. OTCQX is the premier tier of the US OTC markets and will offer US-based investors the opportunity to efficiently trade the Company’s stock.
- Total net expenses in fiscal Q2 2015 increased by $738K over fiscal Q2 2014 driven by increased expenditures on research and development work performed to advance ATB-346 through its development program.
The Corporation’s unaudited Q2 2015 financial statements and MD&A have been filed on SEDAR and an updated corporate presentation is available on the Corporation’s website.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. Antibe’s ATB-352 targets the global need for a safer non- NSAID for acute pain.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.